Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_3
1
20%
Ph phase_1
1
20%
Ph phase_2
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(3)
Other(1)

Detailed Status

Terminated3
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
25.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

completed120%
terminated360%
unknown120%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_1

Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

NCT01891981
unknown

An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

NCT03501615
completedphase_3

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

NCT01829711
terminatedphase_2

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

NCT02227108
terminatedphase_2

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

NCT02338050

Clinical Trials (5)

Showing 5 of 5 trials
NCT01891981Phase 1

Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Terminated
NCT03501615

An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

Unknown
NCT01829711Phase 3

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Completed
NCT02227108Phase 2

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

Terminated
NCT02338050Phase 2

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5